- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 82
- States / cities
- Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 807 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 95
- States / cities
- Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 78 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 878 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 117
- States / cities
- Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Temecula, California • Minneapolis, Minnesota • Portland, Oregon
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Lantus (Insulin glargine), HOE901-U300 (new formulation of insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 811 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 90 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 9 more